98 related articles for article (PubMed ID: 23316969)
21. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
[TBL] [Abstract][Full Text] [Related]
22. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.
Arnold D; Peinert S; Voigt W; Schmoll HJ
Oncologist; 2006 Jun; 11(6):602-11. PubMed ID: 16794239
[TBL] [Abstract][Full Text] [Related]
24. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
El Dika I; Ilson DH
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1085-1092. PubMed ID: 30092682
[TBL] [Abstract][Full Text] [Related]
25. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy.
Tedesco KL; Lockhart AC; Berlin JD
Curr Treat Options Oncol; 2004 Oct; 5(5):393-403. PubMed ID: 15341677
[TBL] [Abstract][Full Text] [Related]
26. Aurora kinase A in gastrointestinal cancers: time to target.
Katsha A; Belkhiri A; Goff L; El-Rifai W
Mol Cancer; 2015 May; 14():106. PubMed ID: 25987188
[TBL] [Abstract][Full Text] [Related]
27. EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?
Kanwar SS; Nautiyal J; Majumdar AP
Curr Drug Targets; 2010 Jun; 11(6):682-98. PubMed ID: 20298154
[TBL] [Abstract][Full Text] [Related]
28. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
Muñoz M; Coveñas R
Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future.
Mulder K; Koski S; Scarfe A; Chu Q; King K; Spratlin J
Oncotarget; 2010 Nov; 1(7):515-529. PubMed ID: 21317448
[TBL] [Abstract][Full Text] [Related]
30. EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.
Nautiyal J; Kanwar SS; Majumdar AP
Curr Protein Pept Sci; 2010 Sep; 11(6):436-50. PubMed ID: 20491625
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Advances in GI Malignancies--Fifth Annual Conference. 13-14 July 2007, Newport Beach, CA, USA.
Alberts SR
IDrugs; 2007 Oct; 10(10):693-5. PubMed ID: 17899484
[No Abstract] [Full Text] [Related]
32. The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.
Desautels D; Harlos C; Czaykowski P
J Carcinog; 2014; 13():13. PubMed ID: 25525412
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy for GI Malignancies, Ready for Prime Time?
Tieniber AD; Perez JE; Hanna AN; DeMatteo RP
Ann Surg Oncol; 2023 Mar; 30(3):1787-1793. PubMed ID: 36273054
[TBL] [Abstract][Full Text] [Related]
34. The therapeutic value of targeting inflammation in gastrointestinal cancers.
Sun B; Karin M
Trends Pharmacol Sci; 2014 Jul; 35(7):349-57. PubMed ID: 24881011
[TBL] [Abstract][Full Text] [Related]
35. From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.
Zoratto F; Rossi L; Giordani E; Strudel M; Papa A; Tomao S
Tumour Biol; 2014 Sep; 35(9):8471-82. PubMed ID: 25062724
[TBL] [Abstract][Full Text] [Related]
36. Targeting metastatic upper gastrointestinal adenocarcinomas.
Spratlin JL; Chu Q; Koski S; King K; Mulder K
World J Clin Oncol; 2011 Mar; 2(3):135-49. PubMed ID: 21611088
[TBL] [Abstract][Full Text] [Related]
37. Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers.
Saoudi González N; Castet F; Élez E; Macarulla T; Tabernero J
Front Oncol; 2022; 12():1021772. PubMed ID: 36300092
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in gastrointestinal cancers.
Grierson P; Lim KH; Amin M
J Gastrointest Oncol; 2017 Jun; 8(3):474-484. PubMed ID: 28736635
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy a Likely New Standard for GI Cancers.
Cancer Discov; 2021 Jan; 11(1):8. PubMed ID: 33239268
[TBL] [Abstract][Full Text] [Related]
40. The Spontaneous Regression of Primary Gastrointestinal Malignancies: An Observational Review.
Minacapelli CD; Leuszkiewicz P; Patel A; Catalano C; Abdelsayed G; Lalos A; Rustgi V
Cureus; 2022 Dec; 14(12):e32970. PubMed ID: 36712716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
